港股异动 | 堃博医疗-B(02216)再涨超18% 月内股价实现翻倍核心产品BroncAblate智衡在中国获批上市

智通财经2025-04-24

智通财经APP获悉，堃博医疗-B(02216)早盘再涨超18%，月内股价实现翻倍。截至发稿，涨8.86%，报1.72港元，成交额1246.33万港元，总市值约9亿港元。消息面上，堃博医疗宣布，公司核心产品，自主研发的全球首款经自然腔道射频消融肺癌治疗器械——BroncAblate智衡一次性使用肺部射频消融导管正式获得中国国家药品监督管理局(NMPA)批准在中国上市，引领肺癌治疗进入超微创介入治疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529614168?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-24 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529614168","market":"us","top_or_hot":-1,"title":"港股异动 | 堃博医疗-B(02216)再涨超18% 月内股价实现翻倍 核心产品BroncAblate智衡在中国获批上市","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，堃博医疗-B(02216)早盘再涨超18%，月内股价实现翻倍。截至发稿，涨8.86%，报1.72港元，成交额1246.33万港元，总市值约9亿港元。消息面上，堃博医疗宣布，公司核心产品，自主研发的全球首款经自然腔道射频消融肺癌治疗器械——BroncAblate智衡一次性使用肺部射频消融导管正式获得中国国家药品监督管理局(NMPA)批准在中国上市，引领肺癌治疗进入超微创介入治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1283795.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 堃博医疗-B(02216)再涨超18% 月内股价实现翻倍 核心产品BroncAblate智衡在中国获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 堃博医疗-B(02216)再涨超18% 月内股价实现翻倍 核心产品BroncAblate智衡在中国获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-24 11:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1283795.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，堃博医疗-B(02216)早盘再涨超18%，月内股价实现翻倍。截至发稿，涨8.86%，报1.72港元，成交额1246.33万港元，总市值约9亿港元。消息面上，堃博医疗宣布，公司核心产品，自主研发的全球首款经自然腔道射频消融肺癌治疗器械——BroncAblate智衡一次性使用肺部射频消融导管正式获得中国国家药品监督管理局(NMPA)批准在中国上市，引领肺癌治疗进入超微创介入治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1283795.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02216","symbol_name":"堃博医疗-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1283795.html","article_id":"2529614168","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529614168","pubTimestamp":1745464434,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，堃博医疗-B早盘再涨超18%，月内股价实现翻倍。截至发稿，涨8.86%，报1.72港元，成交额1246.33万港元，总市值约9亿港元。消息面上，堃博医疗宣布，公司核心产品，自主研发的全球首款经自然腔道射频消融肺癌治疗器械——BroncAblate智衡一次性使用肺部射频消融导管正式获得中国国家药品监督管理局批准在中国上市，引领肺癌治疗进入超微创介入治疗时代。创新器械的增长空间广阔，目前价值严重低估，公司还将持续回购。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02216":"堃博医疗-B","BK1100":"医疗保健设备"},"translate_title":"Changes in Hong Kong stocks Kunbo Medical-B (02216) rose more than 18% again, its stock price doubled within a month, and its core product BroncAblate Zhiheng was approved for listing in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02216":1},"content_text":"智通财经APP获悉，堃博医疗-B(02216)早盘再涨超18%，月内股价实现翻倍。截至发稿，涨8.86%，报1.72港元，成交额1246.33万港元，总市值约9亿港元。消息面上，堃博医疗宣布，公司核心产品，自主研发的全球首款经自然腔道射频消融肺癌治疗器械——BroncAblate智衡一次性使用肺部射频消融导管正式获得中国国家药品监督管理局(NMPA)批准在中国上市，引领肺癌治疗进入超微创介入治疗时代。国元国际本月初曾发布研报指出，公司全球首创的治疗肺癌器械RFII今年有望获批并商业化，市场空间大，随着新产品的不断上市，公司收入有望恢复快速增长，目前PB仅为0.36倍，目前现金及等价物为9.9亿元人民币，而市值仅为5亿港元。创新器械的增长空间广阔，目前价值严重低估，公司还将持续回购。建议积极关注。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529614168","isCrawlerRequest":true}

港股异动 | 堃博医疗-B(02216)再涨超18% 月内股价实现翻倍 核心产品BroncAblate智衡在中国获批上市

精彩评论

港股异动 | 堃博医疗-B(02216)再涨超18% 月内股价实现翻倍核心产品BroncAblate智衡在中国获批上市